Six-Fold Higher Cardiovascular Risk: Eclampsia’s Early Postpartum Threat Demands Urgent Clinical Attention
Posted inCardiology news OB/GYN & Women's Health

Six-Fold Higher Cardiovascular Risk: Eclampsia’s Early Postpartum Threat Demands Urgent Clinical Attention

A nationwide study reveals that eclampsia patients face a 6.9-fold increased risk of cardiovascular disease readmission within the first year postpartum, with stroke risk nearly 13 times higher than normotensive patients. These findings underscore the critical need for enhanced early postpartum cardiac surveillance in women with eclampsia history.
Myocardial Fibrosis Predicts Outcomes in Asymptomatic Severe Aortic Stenosis, But Early Valve Replacement May Not Offer Universal Benefit
Posted inCardiology news

Myocardial Fibrosis Predicts Outcomes in Asymptomatic Severe Aortic Stenosis, But Early Valve Replacement May Not Offer Universal Benefit

The EVOLVED trial reveals that higher myocardial fibrosis burden associates with adverse events in asymptomatic severe aortic stenosis patients, yet early intervention benefits appear nuanced—showing promise for reducing hospitalizations in high-fibrosis patients without clear mortality advantage.
Transfer Before Support: Why Cardiogenic Shock Patients Referred from Regional Centers Face Higher Device-Related Complications
Posted inCardiology Critical Care news

Transfer Before Support: Why Cardiogenic Shock Patients Referred from Regional Centers Face Higher Device-Related Complications

A large observational study reveals that cardiogenic shock patients receiving temporary mechanical circulatory support at regional referral centers before transfer to hub centers experience significantly higher device-related adverse events and mortality compared to those receiving initial support at hub centers, though this difference may be explained by greater illness severity.
Persistent Fibroblast Activation Predicts Heart Failure Progression: [68Ga]FAPI-46 PET/MRI Reveals Distinct Patterns in Ischemic and Nonischemic Cardiomyopathy
Posted inCardiology news

Persistent Fibroblast Activation Predicts Heart Failure Progression: [68Ga]FAPI-46 PET/MRI Reveals Distinct Patterns in Ischemic and Nonischemic Cardiomyopathy

A prospective case-control study demonstrates that myocardial fibroblast activation persists in heart failure patients and follows distinct spatial patterns depending on etiology. Using [68Ga]FAPI-46 PET/MRI, researchers found that higher baseline uptake predicts worse outcomes, suggesting potential for risk stratification and targeted antifibrotic therapy development.
AI-Enhanced ECG Screening Pinpoints Atrial Fibrillation Risk in Older Adults: Key Insights from VITAL-AF Trial
Posted inCardiology news

AI-Enhanced ECG Screening Pinpoints Atrial Fibrillation Risk in Older Adults: Key Insights from VITAL-AF Trial

A VITAL-AF trial analysis reveals that combining ECG-based artificial intelligence with clinical risk scores significantly improves atrial fibrillation screening efficiency. The study demonstrates that high-risk individuals benefit most from screening, with those in the top CH-AI risk decile showing a number-needed-to-screen of just 43 per year.
Exercise Unmasks Multi-Organ Deficits That Predict Heart Failure Risk: Metabolite Signatures Reveal Shared Pathways Across HFpEF and Its Comorbidities
Posted inCardiology news

Exercise Unmasks Multi-Organ Deficits That Predict Heart Failure Risk: Metabolite Signatures Reveal Shared Pathways Across HFpEF and Its Comorbidities

A landmark study reveals that exercise-induced multi-organ physiologic deficits strongly predict incident heart failure with preserved ejection fraction (HFpEF). Using invasive cardiopulmonary testing, metabolomics, and genomics across over 6,000 individuals, researchers identified seven distinct exercise deficits that, when combined, confer nearly 4-fold higher cardiovascular risk and implicate shared metabolic pathways with obesity, diabetes, and renal disease.
Ticagrelor Falls Short: TUXEDO-2 Trial Challenges Antiplatelet Choice in Diabetic Patients With Multivessel Disease
Posted inCardiology news

Ticagrelor Falls Short: TUXEDO-2 Trial Challenges Antiplatelet Choice in Diabetic Patients With Multivessel Disease

The TUXEDO-2 trial reveals that ticagrelor did not meet noninferiority criteria compared with prasugrel in diabetic patients with multivessel coronary artery disease undergoing PCI. At 1 year, the primary composite endpoint of death, MI, stroke, or major bleeding occurred in 16.6% vs 14.2% of patients, suggesting prasugrel may offer better outcomes in this high-risk population.
Why Exercise Blood Pressure Alone May Miss Cardiovascular Risk—and What Combining It With Fitness Reveals
Posted inCardiology news

Why Exercise Blood Pressure Alone May Miss Cardiovascular Risk—and What Combining It With Fitness Reveals

The EXERTION study of 12,743 individuals demonstrates that exercise systolic blood pressure relative to aerobic fitness (SBP/METPeak) is a powerful predictor of cardiovascular events, whereas exercise BP alone provides no prognostic value. This finding challenges current screening practices and suggests a more nuanced approach to identifying hypertension-related cardiovascular risk.
Mobile Health Intervention Achieves 24% Better Blood Pressure Control in Stroke Survivors: PINGS Trial Results from Ghana
Posted inCardiology Neurology news

Mobile Health Intervention Achieves 24% Better Blood Pressure Control in Stroke Survivors: PINGS Trial Results from Ghana

The PINGS trial demonstrates that a 12-month nurse-led mobile health intervention significantly improves blood pressure control among Ghanaian stroke survivors, with 67% achieving target BP versus 43% in usual care. This pragmatic approach leveraging task-shifting and basic mHealth tools offers a scalable model for resource-limited settings.
Efficacy of Blood Pressure-Lowering Pharmacotherapy in Isolated Diastolic Hypertension: A Systematic Synthesis of Evidence
Posted inCardiology Clinical Updates news

Efficacy of Blood Pressure-Lowering Pharmacotherapy in Isolated Diastolic Hypertension: A Systematic Synthesis of Evidence

This review synthesizes recent evidence, including a landmark 2026 meta-analysis, showing that blood pressure-lowering therapy provides similar cardiovascular benefits in patients with isolated diastolic hypertension compared to those with other hypertension phenotypes, even at low baseline diastolic levels.